HTB

COVID-19

Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19

No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study

COVID-19: pathogenesis and treatment 

US study of HIV positive people with COVID-19 reports worse outcomes with comorbidities and having a CD4 <200

Outcomes from COVID-19 in French cohort of 54 HIV positive people on ART

Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue

COVID-19 reinfection can occur after varying times and with more severe disease

Transmission from children to family members in US childcare setting

BHIVA update guidance for HIV care during second wave of COVID-19

COVID-19 deaths in children and people <21 years old in the US

IDSA guidelines on serologic testing for SARS-CoV-2

Long COVID: Mild infection and sustained long-term complications

Review paper highlights substandard COVID-19 research in both peer-review journals and pre-review websites

COVID-19 outcomes in HIV positive people in two large US cohorts

HIV associated with worse outcomes from COVID-19 in UK ISARIC and OpenSAFELY databases

European and UK doctors review latest studies on HIV and COVID-19 coinfection

Tocilizumab associated with better outcomes from COVID-19 in US study

Famotidine associated with better outcomes from COVID-19

INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555

US activists ensure people living with HIV can enrol in COVID-19 vaccine studies

HIV organisations oppose active-challenge COVID-19 vaccine studies

AVAC webinar with Barney Graham: COVID-19 vaccine targets, timelines, efficacy and ethical issues

Equitable access to vaccines against COVID-19

Conference opening and making sense of the science

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

Pneumocystis Jirovecii Pneumonia (PJP) mistaken for COVID-19 in late stage undiagnosed: urgency of including HIV testing on admission

NYC cohort reports similar outcomes from COVID-19 in HIV positive vs HIV negative adults

Spanish study reports associations between COVID-19 and HIV treatment including NRTIs

UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19

Review of COVID-19 in people with immune suppression

EMA grants conditional approval for remdesivir in the EU to treat COVID-19

Drug price announced for remdesivir – as US buys up world stock

RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19

Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study

Individualising management of COVID-19 based on real-time inflammatory responses

Further positive reports from tocilizumab to treat COVID-19

Higher mortality from COVID-19 in London study in Asian or Black compared to white participants

UK study reports antibody responses linked to more severe COVID-19 in higher risk populations

Leading SARS-CoV-2 antibody tests meet specificity but fail current sensitivity guidelines

Infectious SARS-CoV-2 in air and on surfaces in London hospitals

US prisoners have higher mortality rates from COVID-19

US SARS-CoV-2 epidemic could see 100,000 cases per day: NIAID head Anthony Fauci to Senate hearing

Research during COVID-19

Vaccine candidates report phase 3 studies after early safety and immune responses in phase 1/2 studies

FDA guidance on COVID-19 vaccine includes minimal target of 50% efficacy

Latest studies on HIV/COVID-19 coinfection

HIV positive people in South Africa at increased risk of dying from COVID-19: first data from country with high prevalence of HIV and TB

Update on Western Cape data: people with HIV have small increased risks from COVID-19

Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study

Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity

FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research

UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall

SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19

Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers

BHIVA/THT updated guidelines for social distancing in the UK

Two PEP studies report no benefit of hydroxychloroquine for preventing CoV-2 infection

COVID-19 harm reduction programmes in Central and Eastern Europe and Central Asia

HIV and COVID-19 coinfection: case reports, retrospective cohorts and outcomes

UK access to remdesivir approved: but MHRA criteria exclude some who could benefit

EMA recommends expanding access to remdesivir

Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit

Convalescent plasma therapy for COVID-19

Treatment with interferon in early COVID-19

Famotidine associated with improved clinical outcomes in people hospitalised with COVID-19

Post navigation